News & Events

News Releases

July 17, 2024

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

April 5, 2024

NGM Bio Announces Closing of Tender Offer

March 19, 2024

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting


October 17, 2022 at 5:00 AM PDT

June 29, 2022 from 11:00 AM to 12:30 PM EDT

May 31, 2022 at 12:00 PM EDT

Contact Information

investor relations

media relations